Medivation Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. The Company's first compound is enzalutamide, an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. Enzalutamide is used for the treatment of patients with metastatic castration-resistant prostate cancer and is being further developed* for earlier stages of prostate cancer, advanced breast cancer, and hepatocellular carcinoma.

Parent Company
San Francisco, US
Medivation was founded in 2004 and is headquartered in San Francisco, US

Medivation Office Locations

Medivation has offices in San Francisco, Washington, Jersey and New York
San Francisco, US (HQ)
525 Market St

Medivation Data and Metrics

Medivation Summary

Founding Date

Medivation is a subsidiary of Pfizer

Medivation Financial Metrics

USDFY, 2013FY, 2014

Operating expense total

295.2 m428.6 m


(22.2 m)281.8 m

Net Income

(42.6 m)276.5 m
USDFY, 2013FY, 2014FY, 2015


228.8 m502.7 m225.9 m


18 m12.3 m15.9 m

Current Assets

354 m721.9 m634.2 m


17 m41.2 m58.1 m


10 m18.6 m

Total Assets

392.7 m911.6 m1.4 b

Current Liabilities

95.7 m119.7 m266.1 m

Additional Paid-in Capital

410.4 m506.2 m684.8 m

Retained Earnings

(334.2 m)(57.7 m)186.2 m

Total Equity

76.9 m449.3 m872.7 m

Financial Leverage

5.1 x2 x1.6 x
USDFY, 2013FY, 2014FY, 2015

Net Income

(42.6 m)276.5 m244.7 m


(4 m)301 k(4.6 m)

Accounts Payable

1.7 m

Cash From Operating Activities

(68.2 m)273.9 m

Purchases of PP&E

(7.5 m)(10.5 m)(19.5 m)

Cash From Investing Activities

216.8 m(17.5 m)(431 m)

Short-term Borrowings

(12 k)

Cash From Financing Activities

8.9 m50.8 m(65.8 m)

Interest Paid

6.8 m6.8 m3.6 m

Income Taxes Paid

(127 k)1.5 m2.1 m

Traffic Overview of Medivation

Medivation News and Updates

Breakingviews: The Flaws in Pfizer’s Plan to Acquire Medivation

A heated auction and back-of-the-envelope math hint that the buyer is overpaying.

Pfizer’s Medivation Deal May Not Be Enough

The deal may even raise its taxes instead of lowering them.

Pfizer to Buy Cancer Drug Maker in $14 Billion Deal

The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.

Pfizer Is Buying Cancer Drug Maker Medivation

For $14 billion

Pfizer buying Medivation in deal valued at about $14B

NEW YORK (AP) — Pfizer will pay about $14 billion in cash for the cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.The New York drugmaker said Monday that it will pay $81.50 per Medivation s…
Show more

Medivation Company Life and Culture

You may also be interested in